Submissions for variant NM_000059.4(BRCA2):c.6088A>G (p.Asn2030Asp)

dbSNP: rs1555284539

Total submissions: 5

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Ambry Genetics	RCV000574021	SCV000668795	uncertain significance	Hereditary cancer-predisposing syndrome	2022-08-16	criteria provided, single submitter	clinical testing	The p.N2030D variant (also known as c.6088A>G), located in coding exon 10 of the BRCA2 gene, results from an A to G substitution at nucleotide position 6088. The asparagine at codon 2030 is replaced by aspartic acid, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Labcorp Genetics (formerly Invitae), Labcorp	RCV000696990	SCV000825577	uncertain significance	Hereditary breast ovarian cancer syndrome	2022-04-20	criteria provided, single submitter	clinical testing	This sequence change replaces asparagine, which is neutral and polar, with aspartic acid, which is acidic and polar, at codon 2030 of the BRCA2 protein (p.Asn2030Asp). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 483101). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
University of Washington Department of Laboratory Medicine, University of Washington	RCV000574021	SCV003850913	likely benign	Hereditary cancer-predisposing syndrome	2023-03-23	criteria provided, single submitter	curation	Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673).
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV003226326	SCV003923287	uncertain significance	not specified	2023-03-02	criteria provided, single submitter	clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV005000278	SCV005624483	uncertain significance	not provided	2024-05-10	criteria provided, single submitter	clinical testing	The BRCA2 c.6088A>G (p.Asn2030Asp) variant has been reported in the published literature in a tumor sample of an individual with endometrial cancer (PMID: 38282550 (2024)). This variant has also been described to be located in a region of the BRCA2 gene that is tolerant to missense sequence changes (PMID: 31911673 (2020)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant.